Analysts' Top 5 Price Targets of September 15, 2025
Reading Time: 3 minutes
Ocular Therapeutix [US67576A1007]: Chardan Capital starts coverage with Buy and a price target of $21 (63% upside potential) The focus of the positive assessment is the innovative drug AXPAXLI, which is currently in clinical development and offers significant potential for the treatment of two common eye diseases - wet age-related macular degeneration (wAMD) and non-proliferative diabetic retinopathy (NPDR). The drug's introduction will occur gradually over several months, accompanied by two ongoing Phase 3 studies (SOL-1 and SOL-R). Initial data...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
